Evidence map›Paper›PMID 36692665›Full record

ArticleJournal of nephrology2023

Kidney and lung crosstalk during critical illness: large-scale cohort study.

Alessandra Tomasi, Xuan Song, Ognjen Gajic, Kianoush Kashani

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Journal of nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Observational
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Alessandra TomasiInternal Medicine Residency Program, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Xuan SongICU, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong, China.
Ognjen GajicDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Kianoush KashaniDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA. Kashani.Kianoush@mayo.edu.ORCID 0000-0003-2184-3683
Mayo Clinic in Arizona · USMayo Clinic · USShandong Provincial Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe relationship between the lung and kidney investigated in animal and clinical models has demonstrated substantial crosstalk. We aimed to evaluate the association between single vs. concurrent AKI and ARDS and its impact on patient outcomes. Secondly, we aimed to assess whether the order of appearance of these pathologies affected patient outcomes in patients with both diseases.

methodsThis single-center retrospective cohort study included adult patients admitted to the ICU from January 1, 2007 through May 1, 2018 (n = 76,988). Baseline characteristics and outcomes were compared among patients without ARDS or AKI and those with one or both ARDS and AKI. We also assessed outcomes across the order of appearance of these diseases among patients with both AKI and ARDS.

resultsWe enrolled 76,988 unique patients in the final analysis: 47,043 patients with neither AKI nor ARDS, 491 patients with ARDS alone, 27,928 patients with AKI alone, and 1,526 patients with both ARDS and AKI. Patients with both ARDS and AKI had higher ICU (21.2%) and hospital (28.4%) mortality compared to patients with ARDS alone (9.0% ICU mortality, 14.0% hospital mortality) or AKI alone (4.4% ICU mortality, 8.4% hospital mortality) (p < 0.001). These findings remained unchanged after adjusting for illness severity and comorbidities. Of the 1136 patients with both AKI and ARDS, 136 (12%) developed AKI first, 303 (27%) ARDS first, and 697 (61%) had simultaneous diseases. Patients who developed ARDS after AKI had significantly increased ICU (29.4%) and hospital (36.8%) mortality compared to patients who developed AKI after ARDS (13.9% ICU mortality, 21.5% hospital mortality) (p < 0.001).

conclusionsThe combination of AKI and ARDS leads to worse outcomes, including longer hospital and ICU lengths of stay, higher mortality, longer kidney replacement therapy, and longer ventilation requirements than in patients with AKI or ARDS alone. Among patients with both diagnoses, those who developed ARDS after AKI had the highest mortality.

Indexed as

Acute Kidney InjuryRespiratory Distress SyndromeCohort StudiesCritical IllnessHospital MortalityHumansIntensive Care UnitsKidneyLungRetrospective StudiesAcute kidney injuryAcute respiratory distress syndromeCritical illnessKidney replacement therapyMechanical ventilator

Identifiers

PMID36692665
OpenAlexW4317868077

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.